Biomarkers in systemic lupus erythematosus: II. Markers of disease activity

Illei, Gabor G.; Tackey, Edward; Lapteva, Larissa; Lipsky, Peter E.

doi:10.1002/art.20345

Cited by 134 publications

(136 citation statements)

References 144 publications

(207 reference statements)

Supporting

Mentioning

117

Contrasting

Unclassified

Order By: Relevance

“…14 No statistically significant differences between SLE patients and healthy controls were observed when the À794 (CATT) [5][6][7][8] genotype and allele distributions were compared. Table 3 shows data of haplotype frequencies in SLE patients and healthy controls.…”

Section: Resultsmentioning

confidence: 98%

“…[1][2][3][4] In this respect, several studies support that cytokines play an important role in the development and progression of the autoimmune diseases. 5,6 Macrophage migration inhibitory factor (MIF) is an immunoregulatory cytokine that has proinflammatory, hormonal and enzymatic activities, and it is expressed in a wide variety of cell types including macrophages, B and T cells. 7,8 There are several lines of evidence supporting the MIF gene as a good candidate in inflammatory disorders, such as SLE.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evidence of association of macrophage migration inhibitory factor gene polymorphisms with systemic lupus erythematosus

et al. 2006

View full text Add to dashboard Cite

The aim of this study was to evaluate the potential association of functional polymorphisms of macrophage migration inhibitory factor with systemic lupus erythematosus. Our study includes 711 systemic lupus erythematosus (SLE) patients and 755 healthy controls. We genotyped the migration inhibitory factor (MIF) À173G/C using a polymerase chain reaction (PCR) system with predeveloped TaqMan allelic discrimination assay and the MIF À794 CATT n microsatellite polymorphism using a PCR-fluorescent method. A statistically significant difference in the distribution of the MIF À173*C allele between SLE patients and controls (P ¼ 0.004, OR ¼ 1.34, 95% CI ¼ 1.05-1.27) was observed. In addition, the frequency of the MIF À173 *C/C genotype was higher in SLE patient (P ¼ 0.002, OR ¼ 2.58, 95% CI ¼ 1.32-5.10). No differences in the distribution of CATT n were found. However, the haplotypes analyses showed that only the CATT 7 -MIF À173 *C haplotype was associated with a higher susceptibility to SLE (P ¼ 0.001, OR 1.84, 95% CI 1.35-2.79). No association with clinical features was detected in any case. These results suggest that both, MIF À173 *C allele and CATT 7 -MIF À173*C haplotype, confer susceptibility to SLE in our population.

show abstract

Section: Resultsmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

Evidence of association of macrophage migration inhibitory factor gene polymorphisms with systemic lupus erythematosus

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Despite decades of advances in our understanding of the pathogenesis of SLE, few lupus biomarkers have been validated and widely accepted (25,26). Perhaps the most important consequence of this deficiency is the reluctance of the pharmaceutical industry, with promising therapeutics in hand, to embark on lengthy and costly clinical trials without reliable and accepted measures of clinical improvement (27).…”

Section: Discussionmentioning

confidence: 99%

Reticulocytes bearing C4d as biomarkers of disease activity for systemic lupus erythematosus

Liu

Manzi

Kao

et al. 2005

Arthritis & Rheumatism

View full text Add to dashboard Cite

Objective. There is an urgent need for biomarkers with which to monitor disease activity in patients with systemic lupus erythematosus (SLE). We recently showed that abnormal levels of C4d, an activationderived fragment of complement component C4, are deposited on the surface of erythrocytes from patients with SLE. This study focused on reticulocytes, the youngest and shortest-lived erythrocytes (lifespan 24-48 hours), with the objective of testing our hypothesis that when reticulocytes emerge from the bone marrow, they are immediately exposed to and acquire C4d at levels proportionate to the extent of complement activation at that time, thereby reflecting disease activity in SLE.Methods. We conducted a cross-sectional study of 156 patients with SLE, 140 patients with other diseases, and 159 healthy controls. Levels of C4d on the surface of reticulocytes were examined using a 2-color flow cytometric assay. The results were analyzed for correlations with SLE disease activity.Results. A wide range of increased levels of reticu-

show abstract

“…Based on scientific and clinical rationale, a biomarker is defined as a measurement, including but not limited to a genetic, biological, biochemical, molecular, or imaging event whose alterations correlate with the pathogenesis and/or manifestations of a disease and can be evaluated qualitatively and/or quantitatively in laboratories [Illei et al 2004a[Illei et al , 2004b. Given the rapid advance in the understanding of SLE pathogenesis and development of new technologies, an impressive spectrum of SLE biomarkers has been accrued during the past few years.…”

Section: Introductionmentioning

confidence: 99%

Biomarkers in systemic lupus erythematosus: challenges and prospects for the future

Liu

Kao

Manzi

et al. 2013

Therapeutic Advances in Musculoskeletal

105

View full text Add to dashboard Cite

Abstract:The search for lupus biomarkers to diagnose, monitor, stratify, and predict individual response to therapy is currently more intense than ever before. This effort is essential for several reasons. First, epidemic overdiagnosis and underdiagnosis of lupus, even by certified rheumatologists, leads to errors in therapy with concomitant side effects which may be more serious than the disease itself. Second, identification of lupus flares remains as much an art as it is a science. Third, the capacity to stratify patients so as to predict those who will develop specific patterns of organ involvement is not currently possible but would potentially lead to preventive therapeutic strategies. Fourth, only one new drug for the treatment of lupus has been approved by the US Food and Drug Administration in over 50 years. A major obstacle in this pipeline is the dearth of biomarkers available to prove a patient has responded to an experimental therapeutic intervention. This review will summarize the challenges faced in the discovery and validation of lupus biomarkers, the most promising lupus biomarkers identified to date, and the promise of future directions.

show abstract

Biomarkers in systemic lupus erythematosus: II. Markers of disease activity

Cited by 134 publications

References 144 publications

Evidence of association of macrophage migration inhibitory factor gene polymorphisms with systemic lupus erythematosus

Evidence of association of macrophage migration inhibitory factor gene polymorphisms with systemic lupus erythematosus

Reticulocytes bearing C4d as biomarkers of disease activity for systemic lupus erythematosus

Biomarkers in systemic lupus erythematosus: challenges and prospects for the future

Contact Info

Product

Resources

About